Driving Global Access to Comprehensive Genomic Profiling for all Patients with Cancer

Vision

The Precision Cancer Consortium (PCC) aims to make precision oncology and comprehensive genomic profiling the new normal

Mission

The PCC will foster collaboration to improve global patient access to comprehensive genomic profiling in routine care and clinical trials

A migrating cancer cells
Read More
Decibio Logo
Read More
White cyborg robotic hand pointing his finger to human hand with stretched finger - ai artificial intelligence
Read More

Our Members

A Collaboration to Address Challenges Associated with Precision Oncology

Challenges that are ecosystem related cannot be solved by one stakeholder of the healthcare system alone.  The PCC facilitates collaboration of pharma/biotech companies to address challenges regarding access, awareness, and research and development of comprehensive genomic testing for cancer patients globally

PCC Strategic Objectives

Definition of ‘Comprehensive’

The PCC considers comprehensive genomic profiling (CGP) to include all genomic biomarkers necessary to support clinical decisions in terms of access to currently available targeted therapies and clinical trial enrolment for a given cancer indication

Rationale for Consortium Approach

Challenges that are ecosystem related cannot be solved by one stakeholder of the healthcare system alone. The PCC facilitates collaboration of pharma/biotech companies to address challenges regarding access, awareness, and research and development of comprehensive genomic testing for cancer patients globally